Brief: G1 Therapeutics Completes Enrollment In Global Multi-Center Phase 3 Clinical Trial Of Trilaciclib In Patients With Metastatic Colorectal Cancer
13/06/2022 12:33
June 13 (Reuters) - G1 Therapeutics Inc GTHX.O :
* G1 THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
GLOBAL
MULTI-CENTER PHASE 3 CLINICAL TRIAL OF TRILACICLIB IN PATIENTS
WITH METASTATIC COLORECTAL CANCER
Source text for Eikon: ID:nGNX1DVgRH
Further company coverage: GTHX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify